U.S. Market Community

Texas Instruments is in the midst of a multiyear capacity-expansion cycle that is temporarily suppressing free cash flow but materially enhancing the company’s long-term competitive position. The buildout of U.S.-based 300mm analog manufacturing is expected to structurally improve cost efficiency, support higher gross margins, and increase supply-chain resilience.Read more

Take-Two leans heavily on the next Grand Theft Auto, with pre-orders and fresh updates expected soon and a launch set for the holiday season. The big question is whether demand lives up to the hype—or whether another delay or a crowded games market spoils what could be a major turning point for the company.Read more

Investment Assessment Report: AngloGold Ashanti Ltd. 1.Read more

Archer Aviation bets that air taxis can move from flashy prototypes to real-world production, helped by Stellantis’ car-making know-how and a factory being built to churn out aircraft at scale. The big swing factor is getting regulators to approve its Midnight aircraft, which could turn today’s high-risk story into an actual commercial launch.Read more

This company is trying to turn a research-stage boron project into a real producer, and the next round of government decisions could make or break that plan. The upside depends on landing major funding and signing firm customer deals, while delays could force more share sales and leave existing investors with much less.Read more

A little-known step in making AI chips work at scale is turning into a bottleneck: stacking and checking chips and memory so they don’t fail. Onto Innovation may sit right in that chokepoint thanks to a key customer qualification and growing demand from AI memory makers, but delays, tougher competition, or export rules could still derail the story.Read more

Micron is starting to show clear signs that growing demand from AI data centers is lifting sales, profit, and cash coming in the door, not just future promise. The big question now is whether it can keep this momentum going long enough to justify how much optimism is already baked into the stock.Read more

This company’s main dialysis infection product still looks hard to replace, but the market seems to be pricing it as if growth has stalled for good. A pricing change and two upcoming trial readouts could reshape the story quickly, with big upside if things go right—and a clear hit if they don’t.Read more

AMD is pushing hard into the chips that power modern AI, pitching itself as a strong-value alternative to Nvidia as big customers look for options. The big question is whether its next wave of products lands smoothly—or whether a stumble lets Nvidia pull further ahead and the stock cools off.Read more